<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325504</url>
  </required_header>
  <id_info>
    <org_study_id>ORTHOUNION</org_study_id>
    <secondary_id>2015-000431-32</secondary_id>
    <secondary_id>EUCTR2015-000431-32-ES</secondary_id>
    <nct_id>NCT03325504</nct_id>
  </id_info>
  <brief_title>A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union</brief_title>
  <acronym>ORTHOUNION</acronym>
  <official_title>A Multi-centre, Open-label, Randomized, Comparative Clinical Trial of Two Doses of Bone Marrow Autologous MSC+ Biomaterial vs Iliac Crest Autologous Graft, for Bone Healing in Non-union After Long Bone Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORTHOUNION is a multi-centre, open, comparative, randomized, clinical trial with three
      parallel arms that aims to compare the efficacy of three treatments to enhance bone healing
      in patients with long bone non-union.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone injuries represent an important world medical problem producing significant healthcare
      and societal expenditure. While most bone injuries are not severe and are capable of healing
      through bone regeneration by natural callus formation with standard treatments, severe bone
      injuries may not heal, becoming an important unmet clinical need.

      Non-unions, orpseudarthrosis, may occur in 5% to 20% of long-bone fractures that fail to heal
      properly after more than 6 months, with morbidity, prolonged hospitalization, and increased
      expenses. The most commonly accepted standard augmentation to procure fracture and non-union
      healing consists of autologous bone grafting, obtained from the same patient in a different
      surgical site and transplanted to the reconstruction site. However, autologous bone grafting
      has some drawbacks (such as persistent pain, scar, late recovery, limited amount of bone,
      etc) and a limited regeneration efficacy (success rate of about 74%) and high societal cost.
      Culture-expanded autologous MSCs combined with biphasic calcium phosphate (BCP) biomaterial
      granules have been claimed as a solid regenerative medicine alternative to autologous bone
      grafting in non-unions, although current data are limited. In this context, the ORTHOUNION
      initiative focuses on the opportunity to test the hypothesis of superiority of MSC, the
      investigational ATMP, versus the currently accepted standard therapy, iliac crest bone
      autograft to biologically augment surgical treatment of long-bone non-unions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone consolidation</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>The percentage of bone consolidation in the comparator treatment arm ( iliac crest autograft) and experimental treatment arm (mesenchymal cells).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone consolidation</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>To compare bone consolidation between the experimental arms and the comparator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Bone consolidation</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare bone consolidation, using the REBORNE scale, between the experimental arms and the comparator.
The REBORNE scale is an ad-hoc and validated scale, developed by Gomez Barrena et al. (article currently under preparation) as a modification of the RUST score (Whelan, 2010; Journal of Trauma). In the REBORNE scale, the presence/absence of radiological consolidation is evaluated on a total of 4 cortices. Score range from 0 (no bone callus visible) to 4 (callus present with same density as cortical). The total score will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare pain (by Numeric Rating Scale [NSR]) between the experimental arms and the comparator.
The NRS is a scale that rates the patient´s pain from 0-10 (0= no pain, 10= worst pain), at the time of the visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare the rate of complications between the experimental arms and the comparator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare the health status (by using the Short Form-36 Health Questionnarie) between treatment arms.
The SF-36 questionnaire is a validated, widely used patient-reported health survey which measures their physical and mental health status. It consists of 36 questions organized in 8 dimensions. The total score will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Non Union Fracture</condition>
  <arm_group>
    <arm_group_label>hBM-MSCs-Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Cultured Mesenchymal Cells +Biomaterial (Low Dose): 100x106 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hBM-MSCs-High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Cultured Mesenchymal Cells+Biomaterial (High Dose): 200x106 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autollogous Illiac crest graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous Iliac Crest Grafting</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultured Mesenchymal Cells</intervention_name>
    <description>Cultured Mesenchymal Cells obtained from expanded bone marrow</description>
    <arm_group_label>hBM-MSCs-Low Dose</arm_group_label>
    <arm_group_label>hBM-MSCs-High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous iliac crest graft</intervention_name>
    <description>Autologous iliac crest grafting</description>
    <arm_group_label>Autollogous Illiac crest graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65, both sexes

          2. Traumatic isolated closed or open Gustilo I and II, IIIA and IIIB humerus, tibial or
             femur diaphyseal or metaphysodiaphyseal fracture with a status of atrophic,
             oligotrophic or normotrophic non-union.

          3. Able to understand, accept and sign informed consent

          4. Medical health coverage

          5. Able to understand and accept the study constraints

        Exclusion Criteria:

          1. Hypertrophic non-unions

          2. Segmental bone loss requiring specific therapy (bone transport, vascularized graft,
             large structural allograft, megaprosthesis, etc)

          3. Unrecovered vascular or neural injury

          4. Other fractures causing interference with weight bearing

          5. Visceral injuries or diseases interfering with callus formation (severe
             cranioencephalic trauma, etc.)

          6. Active infection of any location and aetiology

          7. Surgical contraindication of any cause

          8. Pregnancy, breast feeding women and women who are of childbearing age and not
             practicing adequate birth control.

          9. Malignant tumour (past history or concurrent disease)(except carcinoma in situ or
             basalioma in remission)

         10. History of bone harvesting on iliac crest contraindicating new iliac crest bone graft
             harvesting or bone marrow collection

         11. Insulin dependent diabetes

         12. Any evidence (confirmed by PCR) of active infection with HIV, Hepatitis B or Hepatitis
             C infection

         13. Any evidence of Syphilis

         14. Known allergies to products involved in the production process of MSC

         15. Corticoid or immunosuppressive therapy more than one week in the three months prior to
             study inclusion

         16. Autoimmune inflammatory disease

         17. Current treatment by biphosphonates not stopped three months prior to study inclusion

         18. Impossibility to meet at the appointments for the follow up

         19. Participation in another therapeutic trial in the previous 3 months

         20. Second non-union in case of bilateral or multiple non-unions (only one non-union per
             patient will be included in the trial)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Gomez-Barrena, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique Gomez-Barrena, Prof</last_name>
    <phone>+34912071204</phone>
    <email>enrique.gomezbarrena@uam.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Avendano-Sola, MD</last_name>
    <phone>+34911916479</phone>
    <email>cristina.avendano@uam.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Rosset, Dr</last_name>
      <email>rosset@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Rosset, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Trauma, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>8907581</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Gebhard, Prof</last_name>
      <email>florian.gebhard@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Florian Gebhard, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Baldini, Prof</last_name>
      <email>nicola.baldini@ior.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Baldini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital U. Puerta de HIerro-Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo de la Cuadra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínica San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Marco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Caba, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Vaquero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital U. La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Cordero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de Cirugía Ortopédica y Traumatología &quot;A&quot;, Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gomez-Barrena, Prof</last_name>
      <email>enrique.gomezbarrena@uam.es</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://orthounion.eu</url>
    <description>Webpage of the Orthounion Study</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Madrid</investigator_affiliation>
    <investigator_full_name>Prof Enrique Gomez-Barrena</investigator_full_name>
    <investigator_title>Full Professor and Chair of orthopaedic surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

